
|Videos|March 29, 2021
Belantamab Mafodotin in Clinical Practice for Heavily Pretreated MM
Author(s)Targeted Oncology
Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.






































